How do you make a FIP cat comfortable?

Therefore, treatment of FIP is aimed at making an affected cat comfortable. The cat should be encouraged to eat, and stress should be avoided. Treatments with immunosuppressive drugs, such as corticosteroids, or immu- nomodulators are often used, but the benefits are limited.

Should you euthanize a cat with FIP?

How do you know when to euthanize a cat that has FIP? This is a decision only you can make, and it is a difficult one. I would never suggest euthanizing a cat, even with FIP, as long as it looks and acts fairly normal. Miracles do happen, but they can’t happen unless they are provided time to happen.

Is polyprenyl immunostimulant effective in cats with non-effusive FIP?

Feline infectious peritonitis (FIP) is a fatal disease with no clinically effective treatment. This field study evaluated treatment with Polyprenyl Immunostimulant (PI) in cats with the non-effusive form of FIP.

What is polyprenyl immunostimulant™?

It is a very safe product which aids in the reduction of clinical signs resulting from rhinotracheitis infection in cats 8 weeks of age or older. Polyprenyl Immunostimulant™ is often referred to as PI or PPI. Polyprenyl Immunostimulant™ reprograms the cat’s innate immunity, restores quality of life, returning your cat to a healthy and happy self.

How much polyprenyl can I give my Cat?

Polyprenyl Immunostimulant™ is administered orally; a single dose equals 0.25 ml/kg. The recommended dosage is two oral doses of Polyprenyl Immunostimulant™ daily for 15 days. Safety studies in 390 cats showed that oral administration of 0.5 mg/kg of Polyprenyl Immunostimulant™ twice daily for 15 days is safe for cats eight weeks of age or older.

How long do you give polyprenyl immunostimulant?

Polyprenyl Immunostimulant is administered orally; a single dose equals 0.25 ml/kg. Two oral doses of Polyprenyl Immunostimulant should be administered daily for 15 days. Forty 10 to 11 week old, specific pathogen-free cats of both sexes were enrolled into placebo-controlled, randomized, double-blinded virus challenge study.